Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Study of Paclitaxel in Combination With BOS172722, a Monopolar Spindle 1 Kinase Inhibitor, in Patients With Advanced Nonhaematologic Malignancies

NCT03328494 is registered in ClinicalTrials.gov with Boston Pharmaceuticals as lead sponsor.

NCT NCT03328494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03328494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Study of Paclitaxel in Combination With BOS172722, a Monopolar Spindle 1 Kinase Inhibitor, in Patients With Advanced Nonhaematologic Malignancies
Lead sponsor
Boston Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
October 13, 2017
Completion date
March 16, 2021
Enrollment
38 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced nonhaematologic malignancies